2007;50:584 90. 661. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369 79. 662. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121:357 65. 663. Morel O, Muller C, Jesel L, et al. Impaired platelet P2Y12 inhibi- tion by thienopyridines in chronic kidney disease: mechanisms, clini- cal relevance and pharmacological options. Nephrol Dial Transplant. 2013;28:1994 2002. 664. Park SH, Kim W, Park CS, et al.A comparison of clopidogrel responsive- ness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104:1292 5. 665. Morel O, El GS, Jesel L, et al. Cardiovascular mortality in chronic kid- ney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57:399 408. 666. Woo JS, Kim W, Lee SR, et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high- maintenance dose of clopidogrel: results of the effect of platelet inhibi- tion according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J. 2011;162:1018 25. 667. Alexopoulos D, Panagiotou A, Xanthopoulou I, et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialy- sis and with high on-treatment platelet reactivity. J Thromb Haemost. 2011;9:2379 85. 668. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. 